scholarly journals Measured and Predicted Basal Metabolic Rate in Inflammatory Bowel Disease Patients

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 624-624
Author(s):  
Luiz Dos Anjos ◽  
Tatiana Campos ◽  
Juliana Dantas ◽  
Fernanda Fernandes ◽  
Vivian Wahrlich
Keyword(s):  
Inflammatory Bowel Disease ◽  
Metabolic Rate ◽  
Basal Metabolic Rate ◽  
Bowel Disease ◽  
Anthropometric Measures ◽  
Predictive Equations ◽  
Women Subjects ◽  
Funding Sources ◽  
Chron's Disease ◽  
Inflammatory Bowel

Abstract Objectives To measure basal metabolic rate (BMR) and to compare the values with estimated BMR from international and local predictive equations in inflammatory bowel disease (IBD) patients. Methods A total of 72 (38 women) subjects with Chron's disease (n = 45, 19 women) and ulcerative colitis (n = 27, 19 women) from an outpatient care unit in Rio de Janeiro, Brazil, agreed to participate in the study. Anthropometric measures were obtained using standard procedures. Percent body fat (PBF) was assessed by DXA. BMR was measured (BMRm) by indirect calorimetry (Vmax Encore 29) under standardized conditions and compared with BMR estimated by internationally-recommended (Schofield, 1985) and locally-developed (Anjos et al., 2014) predictive equations. Bias was calculated as estimated - measured BMR. Results The mean ± SD (range) age was 38.0 ± 11.3 (20.1 – 58.3) years with a mean BMI of 24.7 ± 4.5 (16.1 – 39.1) kg.m−2 and PBF of 32.2 ± 9.1 (9.7 – 53.4). BMRm was significantly lower in women (1169.3 ± 205.0) than men (1439.0 ± 197.5) kcal.day−1. The Schofield's equations significantly overestimated BMR for both women (bias of 204.0 ± 148.3 kcal.day−1 or 17.4%) and men (306.7 ± 171.0 kcal.day−1 or 21.3%). The locally-developed equation yielded nonsignificant estimates for both women (−5.8 ± 143.7 kcal.day−1 or −0.5%) and men (−19.9 ± 165.5 kcal.day−1 or −1.4%). Conclusions The findings of the present study indicate that internationally-recommended BMR predictive equations are not accurate to estimate BMR in IBD patients in a tropical setting. As observed in samples of healthy adults from the same city, the locally-developed BMR equations yield unbiased and accurate estimates for IBD patients. Funding Sources CNPq (310,461/2016–20) and FAPERJ (E-26/202.514/2018; E-26/203.068/2018; E-26/203.068/2017; E-26/202.520/2016; E-26/210.747/2016).

Development of new predictive equations for basal metabolic rate in Iranian healthy adults: negligible effect of sex

2020 ◽  
pp. 1-10
Author(s):  
Bahareh Nikooyeh ◽  
Nastaran Shariatzadeh ◽  
Ali Kalayi ◽  
Maliheh Zahedirad ◽  
Tirang R. Neyestani
Keyword(s):  
Metabolic Rate ◽  
Thyroid Function ◽  
Basal Metabolic Rate ◽  
Age Groups ◽  
Thyroid Function Tests ◽  
Anthropometric Measures ◽  
Predictive Equations ◽  
Normal Thyroid Function ◽  
Asian People ◽  
Predictive Formulas

Abstract. Some studies have reported inaccuracy of predicting basal metabolic rate (BMR) by using common equations for Asian people. Thus, this study was undertaken to develop new predictive equations for the Iranian community and also to compare their accuracy with the commonly used formulas. Anthropometric measures and thyroid function were evaluated for 267 healthy subjects (18–60 y). Indirect calorimetry (InCal) was performed only for those participants with normal thyroid function tests (n = 252). Comparison of predicted RMR (both kcal/d and kcal.kg.wt−1.d−1) using current predictive formulas and measured RMR revealed that Harris-Benedict and FAO/WHO/UNU significantly over-estimated and Mifflin-St. Jeor significantly under-estimated RMR as compared to InCal measurements. In stepwise regression analysis for developing new equations, the highest r2 (=0.89) was from a model comprising sex, height and weight. However, further analyses revealed that unlike the subjects under 30 y, the association between age and the measured RMR in subjects 30 y and plus was negative (r = −0.241, p = 0.001). As a result, two separate equations were developed for these two age groups. Over 80 percent of variations were covered by the new equations. In conclusion, there were statistical significant under- and over-estimation of RMR using common predictive equations in our subjects. Using the new equations, the accuracy of the calculated RMR increased remarkably.

scholarly journals Effectiveness of Fiber Supplementation for Gastrointestinal Function: An Umbrella Review of Meta-Analyses

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 1133-1133
Author(s):  
Marc McRae
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Bowel Disease ◽  
Meta Analysis ◽  
Significant Heterogeneity ◽  
Umbrella Review ◽  
Funding Sources ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Meta Analyses

Abstract Objectives To determine if published meta-analyses support the use of fiber supplementation in the treatment of constipation and the dietary support for gastrointestinal disorders such as irritable bowel syndrome, and inflammatory bowel disease. Methods A PubMed search from January 1, 1980 to November 30, 2019 was conducted with the following search strategy: (fiber OR fibre) AND (meta-analysis OR systematic review) AND (constipation OR irritable bowel syndrome OR inflammatory bowel disease). Meta-analyses that provided quantitative statistical analysis with a measured effect size were retrieved and accepted into this review. The following was extracted and entered into an Excel spreadsheet: number of publications included in the meta-analysis, number of total participants, fiber type and daily dose, pooled treatment effects for clinical endpoints and/or summary relative risks (RR's). Results Thirteen meta-analyses support dietary fiber supplementation for patients with constipation and irritable bowel syndrome, but the significant heterogeneity and publication bias undermines the support for using dietary fiber supplementation on these conditions. Conclusions This umbrella review of meta-analyses finds some benefits for recommending fiber supplementation to patients with constipation and irritable bowel syndrome, but significant heterogeneity and publication bias undermines this support. Funding Sources No funding sources were utilized.

scholarly journals Anthropometric Measures in Adolescents With Inflammatory Bowel Disease: A Population-Based Study

2018 ◽  
Vol 25 (6) ◽  
pp. 1061-1065 ◽  
Author(s):  
Itai Ghersin ◽  
Neron Khateeb ◽  
Lior H Katz ◽  
Saleh Daher ◽  
Raanan Shamir ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Population Based ◽  
Anthropometric Measures ◽  
Population Based Study ◽  
Inflammatory Bowel

scholarly journals Role of therapeutic drug monitoring of azathioprine and thiopurine methyltransferase enzyme status in patients with inflammatory bowel disease: Indian scenario

2020 ◽  
Vol 9 (10) ◽  
pp. 1618
Author(s):  
Maninder Singh ◽  
Sandeep Kaushal ◽  
Kanchan Gupta ◽  
Ajit Sood
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Therapeutic Drug Monitoring ◽  
Bowel Disease ◽  
Drug Monitoring ◽  
Anal Verge ◽  
Current Status ◽  
Therapeutic Drug ◽  
Chron's Disease ◽  
Inflammatory Bowel

Inflammatory bowel disease is mainly caused by dysragulated immune system. Inflammatory bowel disease incidences are rising in Asian countries with difficulty in their diagnosis and managements. There is rising the incidences and prevalence rate in India. Inflammatory bowel disease has two major subtypes Ulcerative colitis and chron’s disease. In ulcerative colitis inflammation occurs in lower part of large intestine that extend from anal verge to proximal colon while in case of chron’s disease there is transmural inflammation of gastrointestinal tract. This review is to provide comprehensive review focused on the current status of therapeutic drug monitoring of azathioprine metabolites in patients of inflammatory bowel disease.

scholarly journals P753 Elevation of liver enzymes in a large cohort of patients with inflammatory bowel disease

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S602-S602
Author(s):  
O ATIA ◽  
D Turner ◽  
A Mendelovici ◽  
A Assa ◽  
Y Mozer-Glassberg ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Liver Enzymes ◽  
Drug Induced ◽  
Anthropometric Measures ◽  
Health Maintenance ◽  
Total Incidence ◽  
Israeli Population ◽  
Inflammatory Bowel ◽  
Mixed Pattern

Abstract Background Elevation in liver enzymes (ELE) is often seen in patients with inflammatory bowel disease (IBD). The aim of this study is to assess the incidence, character, chronicity, degree, and etiology of ELE in within the validated epiIIRN cohort which includes all IBD patients in Israel (n = 45,074). Methods We current analysis was performed on data from three of four Health Maintenance Organisations (HMOs), covering 48% of the Israeli population. The identification of Crohn’s disease (CD) and ulcerative colitis (UC) utilised previously validated algorithms. Retrieved data included demographics, anthropometric measures, liver enzymes, medications and other diagnoses codes. Mild ELE was defined from upper normal limit (UNL) to X2 UNL, moderate X3 UNL and severe elevation ≥X4 UNL). The pattern of elevation was defined as hepatocellular (isolated elevation of ALT and/or AST), cholestatic (elevated GGT and/or ALK and bilirubin) and mixed pattern. Chronicity of ELE was defined as brief (<30 days) to chronic (>180 days). Results The total incidence (ever) of ELE in CD patients was 33% (3098/9421) and 28% in UC (2001/7040); p < 0.001. The mean age at ELE was 29.9 years (IQR 17.2–47.5) in CD and 37.9 years (23.2–53.8) in UC (p < 0.001). Hepatocellular pattern had more commonly in UC (54% vs. 47%, p < 0.001) as mixed pattern (22% vs. 20%, p = 0.01), while cholestatic pattern had more commonly in CD (31% vs. 26%, p < 0.001). The ELE was transient in 609 (9%) patients, while 4054 (62%) had chronic ELE. Mild ELE was recorded in 860 (22%) CD patients and 460 (19%) UC, and severe in 328 (8%) CD and 253 (10%) UC. ELE was recorded during the first three months after initiation of thiopurines in 604 (15%) CD and 201 (8%) UC patients (p < 0.001), after biologics in 346 (9%) CD and 62 (3%) UC (p < 0.001), after steroids in 538 (14%) and 272 (11%), respectively (p = 0.01) and after methotrexate in 76 (2%) and 15 (0.6%), respectively (p = 0.001). The incidence of fatty liver was most common in UC (5% vs. 3%, p = 0.006). Conclusion ELE is common complication in IBD patients, more so in UC. When enzymes do increase in CD they tend to reach higher levels. Drug induced liver injury was more common in CD. This study was supported by a grant from the Leona M. and Harry B. Helmsley Charitable Trust.

scholarly journals Intestinal inflammation markers in inflammatory bowel disease

2018 ◽  
Vol 5 (3) ◽  
pp. 829
Author(s):  
Abdullatif Alomair ◽  
Ayman Alswayeh ◽  
Abrar Alhazmi ◽  
Abdullah Alshammari ◽  
Salma Alsaffar ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Serological Markers ◽  
Disease Response ◽  
Peptide Antigens ◽  
The Past ◽  
Outer Membrane Porin ◽  
Chron's Disease ◽  
Inflammatory Bowel

During the past few decades, extensive researches were conducted to identify serological markers in patients with inflammatory bowel disease (IBD) that can reliably diagnose and monitor disease activity and help in predicting relapses. To date, several serological markers have been identified. This review will address the different serological markers and their clinical significance and applicability in medical practice. Serological markers include antibodies against microbial antigens, peptide antigens, autoantibodies, and basic inflammatory markers. Some serological markers such as anti-Saccharomyces cerevisiae antibodies (ASCA) and antibodies against exocrine pancreas (PAB) help the confirmation of the diagnosis of IBD to differentiate it from other non-IBD. Perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) and ASCA can distinguish Chron’s disease and ulcerative colitis. Certain markers can aid stratification of Chron’s disease including antibodies to Pseudomonas fluorescens associated sequence I2 (Anti-I2), antibodies to bacterial flagellin (Anti-CBir1), ASCA, and antibodies to outer membrane porin C (Anti-OmpC). ASCA and pANCA can predict disease response to therapeutic agents (e.g. Infliximab). ASCA can also unaffected family members at risk of developing Chron’s disease.

Sign in / Sign up

Export Citation Format

Share Document